Do Antineoplastic Drugs Play an Additional Role in the Progression of Non-Compaction Cardiomyopathy? A Case Report

DOI: 10.4236/crcm.2020.96021   PDF   HTML   XML   149 Downloads   343 Views  


Non-compaction cardiomyopathy is a rare form of cardiomyopathy; its most common clinical manifestations are heart failure (HF), ventricular arrhythmia, thromboembolism, and sudden cardiac death. We report a rare case of a 63-year-old man with chest tightness, worsening lower leg edema, dyspnea, and decreased exercise tolerance. He had a medical history of gastric cancer treated with subtotal gastrectomy and post-operative chemotherapy with paclitaxel and fluorouracil three years ago. At that time, he was diagnosed with non-compaction cardiomyopathy, and the thickened and reticulated trabecular muscle was exclusively confined to left ventricular apex. Five months ago, he was admitted to our hospital with heart failure and treated for dilated cardiomyopathy, echocardiography revealed severe trabecular noncompact myocardium in both ventricles, which was confirmed by cardiac magnetic resonance imaging (CMR). It is generally accepted that non-compacted myocardium forms in the early embryonic stage, which raises a question in our case whether acquired factors, such as antineoplastic drugs, potentially accelerate the pathological progression of non-compaction cardiomyopathy. Considering there are disparities between current screening tools such as echocardiography and CMR regarding diagnostic criteria, multi-detector CT may be an alternative examination method that could provide a new perspective for diagnosis.

Share and Cite:

Luo, C. , Yang, Y. , Yang, C. , Hao, X. , Duan, Z. , Li, G. and Tian, G. (2020) Do Antineoplastic Drugs Play an Additional Role in the Progression of Non-Compaction Cardiomyopathy? A Case Report. Case Reports in Clinical Medicine, 9, 144-153. doi: 10.4236/crcm.2020.96021.

Conflicts of Interest

The authors declare that they have no competing interests.


[1] Maron, B.J., Towbin, J.A., Thiene, G., et al. (2006) Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807-1816.
[2] Finsterer, J., Stöllberger, C. and Towbin, J.A. (2017) Left Ventricular Noncompaction Cardiomyopathy: Cardiac, Neuromuscular, and Genetic Factors. Nature Reviews Cardiology, 14, 224-237.
[3] Chin, T.K., Perloff, J.K., Williams, R.G., et al. (1990) Isolated Noncompaction of Left Ventricular Myocardium. A Study of Eight Cases. Circulation, 82, 507-513.
[4] Ikeda, U., Minamisawa, M. and Koyama, J. (2015) Isolated Left Ventricular Non-Compaction Cardiomyopathy in Adults. Journal of Cardiology, 65, 91-97.
[5] Taghavi, M., Ghaemian, A., Nabati, M., Farsavian, A. and Shokri, M. (2019) The Coexistence of Left Ventricular Non-Compaction Cardiomyopathy, Significant Coronary Artery Disease and Massive Thrombus Formation in Left Ventricular Cavity: A Rare Case Report. Journal of Clinical Ultrasound, 47, 107-110.
[6] Towbin, J.A. and Jefferies, J.L. (2017) Cardiomyopathies Due to Left Ventricular Noncompaction, Mitochondrial and Storage Diseases, and Inborn Errors of Metabolism. Circulation Research, 121, 838-854.
[7] Towbin, J.A., Lorts, A. and Jefferies, J.L. (2015) Left Ventricular Non-Compaction Cardiomyopathy. The Lancet, 386, 813-825.
[8] Oechslin, E. and Jenni, R. (2011) Left Ventricular Non-Compaction Revisited: A Distinct Phenotype with Genetic Heterogeneity? European Heart Journal, 32, 1446-1456.
[9] Loria, V., Colizzi, C., Vaccarella, M., Franceschi, F. and Aspromonte, N. (2019) Left Ventricular Noncompaction: Cause or Consequence of Myocardial Disease? A Case Report and Literature Review. Cardiology, 143, 100-104.
[10] Sara, J.D., Kaur, J., Khodadadi, R., et al. (2018) 5-Fluorouracil and Cardiotoxicity: A Review. Therapeutic Advances in Medical Oncology.
[11] Dang, C., Guo, H., Najita, J., et al. (2016) Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2, 29-36.
[12] Jenni, R., Oechslin, E., Schneider, J., Attenhofer Jost, C. and Kaufmann, P.A. (2001) Echocardiographic and Pathoanatomical Characteristics of Isolated Left Ventricular Non-Compaction: A Step towards Classification as a Distinct Cardiomyopathy. Heart, 86, 666-671.
[13] Baksi, A.J. and Pennell, D.J. (2015) Cardiomyopathy. In: Advanced Cardiac Imaging, Woodhead Publishing, Cambridge, 399-438.
[14] Rooms, I., Dujardin, K. and De Sutter, J. (2015) Non-Compaction Cardiomyopathy: A Genetically and Clinically Heterogeneous Disorder. Presentation of Two Cases and Review of the Literature. Acta Cardiologica, 70, 625-631.
[15] De Melo, M.D.T., de Araújo Filho, J.B., Parga Filho, J.R., et al. (2015) Noncompaction Cardiomyopathy: A Substrate for a Thromboembolic Event. BMC Cardiovascular Disorders, 15, 7.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.